We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Zymeworks Inc (ZYME) NPV

Sell:$7.01 Buy:$9.05 Change: $0.15 (1.85%)
NASDAQ:2.03%
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$7.01
Buy:$9.05
Change: $0.15 (1.85%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
Sell:$7.01
Buy:$9.05
Change: $0.15 (1.85%)
Market closed |  Prices as at close on 26 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.

Contact details

Address:
108 Patriot Drive, Suite A
MIDDLETOWN
19709
United States
Telephone:
+1 (302) 2748744
Website:
https://www.zymeworks.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ZYME
ISIN:
US98985Y1082
Market cap:
$603.36 million
Shares in issue:
71.22 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kenneth Galbraith
    Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer
  • Paul Moore
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.